Thorough and ongoing testing of electronic health records (EHRs) is key to ensuring their safety and effectiveness. Many health care organizations limit testing to test environments separate from, and often different than, the production environment used by clinicians. Because EHRs are complex hardware and software systems that often interact with other hardware and software systems, no test environment can exactly mimic how the production environment will behave. An effective testing process must integrate safely conducted testing in the production environment itself, using test patients. We propose recommendations for how to safely incorporate testing in production into current EHR testing practices, with suggestions regarding the incremental release of upgrades, test patients, tester accounts, downstream personnel, and reporting.
INTRODUCTION
Ensuring that EHRs are safe and effective is an important and increasingly visible challenge. [1] [2] [3] [4] The quality and safety benefits of EHRs have been long understood, [5] [6] [7] but unintended consequences, malfunctions, and safety issues have also been reported. [8] [9] [10] Recently, the Office of the National Coordinator for Health Information Technology (ONC) released a report focused on safety issues in EHRs 3 and also commissioned the development of a series of proactive EHR risk assessment tools, called the Safety Assurance Factors for EHR Resilience (SAFER) guides. 11, 12 These SAFER guides identify pre-implementation and ongoing testing of EHRs as a key safety practice, 13 and the importance of testing software is, of course, already widely emphasized. [14] [15] [16] [17] [18] In our research, we have undertaken a number of cross-organization evaluations of EHRs as implemented at sites across the country. [19] [20] [21] [22] [23] [24] In each of these projects, we have worked with clinicians, informaticians, and IT personnel to conduct evaluations of their EHRs. In addition to production environments, most sites also have test environments that are designed to mirror the production EHR. Whenever possible, we requested that evaluations be conducted in the "live" production EHR, the same one in use by clinicians, using test patients. In most cases, the sites were able to accommodate our request to test in production, but a minority of sites reported a policy against testing in the production EHR or did not have any test patients configured for testing in production. In other cases, there were significant limitations that prevented reasonable testing in the production environment, such as no test patients admitted to hospital beds (preventing any inpatient testing) or no ability to create laboratory results on test patients in the production environment. In these cases, we fell back to testing in a test or support system environment rather than the production environment. During demonstrations in test environments, we noticed some concerning patterns. In many cases, users conducting demonstrations during our research reported that "this works slightly differ-ently" in production or that they were unable to complete scenarios due to limitations of the testing environment. We also encountered situations during production testing where users noticed that a feature we asked to see (eg, drug-pregnancy checking) was not working in production despite recent successful testing in the test environment.
WHY TEST IN PRODUCTION?
Software testing is a multistep process that encompasses a wide variety of techniques and strategies. The general aims are to verify that software is written as designed and that it is designed as intended. Upgraded and newly developed or implemented EHRs, or features and modules thereof, should be thoroughly tested for both technical issues like system crashes or unexpected results and user-centric issues like problems with usability or workflow. 25 After a system is live, ongoing regression testing should also be conducted to ensure that the system continues functioning as expected, that changes made have not created new issues, and that new problems are identified and addressed. 26 Although it often makes sense to do some of this testing in nonproduction environments, such tests should also be done in production environments to ensure the safety and proper functioning of implemented EHRs.
In our experience, organizations that do not practice testing in production argue that such testing is unnecessary because their test environments accurately replicate their production system. There are at least 2 immediate concerns in response to this claim. First, experience, including several published studies, has identified software errors that were discovered in production environments. [27] [28] [29] Unfortunately, these errors are often found only by end user report, sometimes years after the system is released, and not by any ongoing testing process. Relying on user reports to identify errors can lead to long delays in discovering malfunctions, and this policy de facto pushes production testing onto real patients. In contrast, intentionally and carefully controlled testing in production may more quickly identify problems that did not arise in the test environment. Second, our experience suggests that testing environments can differ greatly from production environments, and almost inevitably there are components of production environments that are not identical to testing environments. Because EHR software runs on physical hardware, and because it typically interfaces with many other pieces of software and devices, it is virtually never the case that a test environment can be used to evaluate true end-to-end functionality or EHR response time. Testing in production offers the ability to test the complete EHR, including any interfaces with outside applications, modules, and devices. 30 This kind of end-to-end testing is often not possible in testing environments, where key features of the production environment may not be configured or available (eg, a lack of interfaces with physical devices such as barcode scanners and label printers has been noted by others 31 ). One case study found that a lab and radiology system that interfaced with a computerized provider order-entry system did not share the same fields for results delivery; as a consequence, test results from the lab and radiology departments were sometimes routed to the wrong provider. 26 Furthermore, testing in production is necessary in order to obtain a true sense of EHR performance and response time, which greatly affect usability and workflow. Even a test environment that is an exact copy of the production environment is typically hosted on different physical or virtual hardware, which can lead to unexpected differences in functionality or performance. Testing environments also generally have much less load than production environments, so they can be faster; conversely, testing environments often have less powerful hardware, so they can be slower. Unless a complete, fully integrated test environment is available that replicates realistic load conditions, testing in production may be the only solution for ensuring end-to-end functionality and adequate response time.
Because of the limitations inherent in test environments, we strongly believe that policies against testing in production are misguided, and that testing in the production environment, with appropriate safeguards, is essential. Of course, we do not recommend that testing in production be the first or main approach for testing; organizations should have one or more testing environments to do most of their testing during the EHR build and to evaluate application and operating system upgrades prior to go-live. However, it is almost always the case that these environments will differ, at least in some manner, from the actual production system, so some means of testing in production is essential. Testing in production, however, can introduce complications and creates a potential risk for harm; thus, considerable care must be taken when conducting such testing.
RECOMMENDED PRACTICES FOR TESTING IN PRODUCTION
In this section we propose recommended practices for safely and effectively testing in production. (For reference, a concise list of these practices can be found in Table 2 at the end of this article.) We have attempted to anticipate some of the risks associated with testing in production and to explain how these recommended practices can help mitigate those risks. We recognize that not all of these recommendations are easy to implement. Further, depending on the availability of IT resources at health care organizations, some of this work may fall to EHR vendors, while other aspects may need to be owned by users.
Incremental release
Before any newly developed or upgraded software systems, features, modules, or content are released into the production environment, they should be tested thoroughly in a designated testing environment, which should mirror the production environment as closely as possible. After initial testing has been completed successfully, the new feature should be moved into the production environment, but enabled for only a limited number of alpha testers who will test it on test patients. Next, the feature should be enabled for a small group of clinician beta testers who will first test it on test patients and then use it for routine care of actual patients with careful monitoring. Once the alpha and beta testing are passed, the feature or upgrade can be released, either in waves (eg, floor by floor or department by department) or all at once, to the rest of the clinical users with careful monitoring for a limited time. Ongoing regression testing of key features should be done on a routine basis by testers (supplemented with automated test scripts) on test patients in the production environment to guard against the inadvertent introduction of new errors.
Test patients
A range of test patients should be created in the production environment with distinctive names. They should be specifically flagged in databases as test patients. If possible, test patient records should be displayed differently in the EHR (perhaps using different color schemes).
The purpose of giving test patients distinctive names is to make it both obvious that they are test patients and less likely that they will be confused with real patients. Good test patient names help decrease the chances of wrong-patient errors and minimize the possibility that testers will accidentally enter an order on a real patient in the production environment. Notably, test patients should not be given "cute" names, such as Santa Claus, as patients may occasionally register under such names, nor should they be given the last name "Test," as some patients actually have this last name ( Table 1 shows the frequency of surnames in the United States that begin with "Test" 32 ). Well-designed test patient names incorporate elements such as numerals, begin with "ZZZ," and include "training" or "testing" as part of the name. For example, "ZZZtestingBWH345, OneTest" and "ZZZUTHtraining5, TwoTest" are well-designed names that obviously refer to test patients and have the added benefit of sorting to the bottom of alphabetical lists. 33 One organization's policy for test patient naming is given in Appendix 1. It is worth noting that just as test environments cannot exactly mirror production environments, test patients do not perfectly reflect real patients (ie, they may have vastly more or significantly less data, may be out of date, or may not be physiologically representative). One good approach is to copy de-identified data from real patients and shift dates to create more realistic test patients.
Failing to make test patients available in the production environment can have tragic consequences if users decide to "test" using a real patient. For example, in 2004, the Institute for Safe Medication Practices (ISMP) reported on an event where, during testing of the drug-allergy alerting mechanism, "an information technology staff member entered an amoxicillin order for a 'live' patient with an amoxicillin allergy. The drug was inadvertently dispensed and administered to the patient, who developed toxic epidermal necrolysis." 34 The ISMP report does not indicate whether test patients were available in the production environment, but this example highlights how serious the effects can be if software is tested on real patients, and it underscores the importance of having clearly identified test patients available for testing.
Test accounts for testers
Testers should use special testing accounts with unique, distinctive user names (eg, ZZZTestDoc7, UTHtester) in the production environment. If the testers also use the production environment for other activities (such as providing patient care), they should have one account for normal use and another account (or accounts) for testing. Testing on live patients (including the tester's own medical record) should be strictly forbidden, and, where possible, it is sensible to restrict testers' accounts to only access test patients in the production environment. Testers should not share testing accounts, and regular (ideally, near real-time) auditing should be performed to ensure that testers are using their privileges appropriately.
The ISMP case discussed above highlights the risk that testers may accidentally take actions on real patients during testing. Another risk, sometimes cited by organizations that do not permit testing in production, is that testers may intentionally misuse their privileges in the production environment, for example by writing prescriptions or accessing protected health information data, which they would not otherwise be able to do in a testing environment. Note that in most organizations, many users (including testers) already have access to the production environment. Controls such as training, auditing, and discipline for users who violate rules have generally proven sufficient to minimize misuse of privileges. The additional measures of restricting testers to test patients and giving them special accounts can also significantly mitigate risks Table 1 . US Census data for 2000 showing size of population with given last name, as well as rank of last name out of all last names reported, for the 7 most common last names that begin with "Test" 32 
Last Name
Count Rank   Testa  8123  4013  Tester  4154  7396  Testerman  3004  9907  Teston  1070  22 443  Test  1037  23 019  Testani  455  44 497  Testo  252  72 022   Table 2 . Summary of recommended practices for safely and effectively testing in production environments
Recommended Practices Common Safety Concerns
Incremental release Thorough testing should initially be performed in a test environment before any changes are released into the production environment. Once initial testing has been passed, the feature should be enabled in the production environment for a limited number of alpha testers who will test it on test patients. Next, the feature should be enabled for a small group of clinician beta testers who will first test it on test patients and then use it for routine care of actual patients with careful monitoring. After beta testing, the feature should be released, either in waves or all at once, to the rest of the target population of clinical users with careful monitoring for a limited time. Ongoing regression testing of key features should be done on a routine basis by testers (supplemented with automated tests) on test patients in the production environment to guard against new errors.
Some "bugs" are difficult for the initial user to detect, thus providing a false sense of security for EHR developers. Widespread release could cause the EHR to "freeze" or corrupt the database. Regression testing scripts must be periodically updated to reflect EHR modifications. 
Downstream personnel
All personnel who may receive downstream results of tests (eg, nurses, laboratory technicians, pharmacists, or billing staff) should be (a) notified about testing before it happens, (b) trained on what to do when they receive a transaction for a test patient in their work area, and (c) invited to provide feedback to testers on actions they receive. 35 Examples of downstream effects include procedures documented in the EHR that are then sent to the billing department, medication orders that are sent to the pharmacy, and laboratory orders that cause labels to print or requisitions to appear in the laboratory. Additionally, work queues and message boxes may be populated by test referrals, orders, and tasks. Thus, downstream personnel should be prepared to handle these types of actions and should be notified when testing is taking place. Furthermore, ensuring that downstream actions work correctly is an important part of testing, and it may be helpful to involve personnel in the testing process by inviting them to report on actions they receive and provide feedback on their utility. This feedback can be an opportunity to uncover issues with system-to-system interfaces and workflow processes. 36 
Reporting
Reports and data extracts should be configured to exclude test patients. As discussed in the test patient section above, test patients should be appropriately flagged in databases so that they can be excluded from quality and productivity measurements, except in cases where the measurements themselves are being tested. 37 These restrictions will prevent test patient data from contaminating quality, productivity, and financial reports.
CONCLUSION
In summary, we believe that testing in the production environment is essential for ensuring the safety of EHRs. The recommended practices, taken together, will increase the fidelity of EHR testing while ensuring safety and preventing harm during the testing process. Organizations with policies that prevent testing in the production environment should carefully reconsider their approaches.
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